# Daruharidra > Daruharidra (Berberis aristata DC.) is a plant used in Ayurveda. Skin diseases and acne (Kushtha/Yauvanpidika): Validated by RCTs showing berberine-containing extracts effective against acne-causing pathogens (P. Berberine is listed in WHO traditional medicine references. ## Key facts - **Botanical name:** Berberis aristata DC. - **Pharmacopoeia status:** Berberine is listed in WHO traditional medicine references. Berberis aristata is included in the Ayurvedic Pharmacopoeia of India. EFSA is conducting ongoing safety assessments for berberine in food supplements. No dedicated WHO monograph exists for Berberis aristata specifically. ## Names and identification | Language | Name | |----------|------| | English | Daruharidra | | Latin/Botanical | *Berberis aristata DC.* | ## Key Phytochemical Constituents - [Berberine](/glossary/compounds-a-c/#berberine) (isoquinoline alkaloid - primary bioactive compound) - [Palmatine](/glossary/compounds-o-q/#palmatine) (protoberberine alkaloid) - [Jatrorrhizine](/glossary/compounds-g-l/#jatrorrhizine) - Oxyberberine - [Berbamine](/glossary/compounds-a-c/#berbamine) (bisbenzylisoquinoline alkaloid) - Karachine - Taxilamine - [Tannins](/reference/tannins/) and phenolic acids ## How does it work? - JAK1/STAT1 pathway suppression: [Berberine](/glossary/compounds-a-c/#berberine) inhibits the JAK1/STAT1 signaling cascade, reducing keratinocyte hyperproliferation and inflammatory cytokine production in psoriasis - MMP-1 and MMP-9 inhibition for anti-aging: [Berberine](/glossary/compounds-a-c/#berberine) inhibits UV-induced MMP-1 and MMP-9 expression, prevents TPA-induced ERK activation and AP-1 DNA binding, protecting collagen and extracellular matrix from degradation - Anti-tyrosinase skin lightening: [Berberine](/glossary/compounds-a-c/#berberine) and Berberis aristata extracts inhibit tyrosinase enzyme activity, reducing melanin biosynthesis for skin lightening and hyperpigmentation correction - Anti-microbial S. aureus inhibition: [Berberine](/glossary/compounds-a-c/#berberine) inhibits Staphylococcus aureus colonization and mast cell degranulation, particularly relevant for eczema management where bacterial infection exacerbates symptoms ## Which traditional uses are supported by research? - Skin diseases and acne (Kushtha/Yauvanpidika): Validated by RCTs showing berberine-containing extracts effective against acne-causing pathogens (P. acnes, S. epidermidis) and inflammatory acne - Skin lightening and exfoliation (Varnya): Traditional scrub preparations validated by tyrosinase inhibition studies showing competitive enzyme inhibition - Eye diseases with skin manifestation (Netra Roga): Traditional use supported by berberine's demonstrated broad [antimicrobial](/reference/antimicrobial/) and anti-inflammatory activity - Wound healing (Vrana): Supported by berberine's anti-inflammatory and antimicrobial mechanisms promoting tissue repair ## What do recent clinical trials show? - Saeidi S, Ghanadian SM, Poostiyan N and others 2024. [Evaluation of the effectiveness of Berberis integerrima Bunge root extract combined with spearmint essential oil in the treatment of acne vulgaris: A randomized controlled clinical trial](https://pubmed.ncbi.nlm.nih.gov/38545754/). *Journal of cosmetic dermatology*. PMID [38545754](https://pubmed.ncbi.nlm.nih.gov/38545754/) · [doi:10.1111/jocd.16291](https://doi.org/10.1111/jocd.16291) Berberis root extract combined with spearmint oil demonstrated significant clinical improvement in acne vulgaris patients in a randomized controlled trial, validating the anti-acne potential of berberine-containing plants. - Duda-Madej A, Lipska P, Viscardi S and others 2025. [Targeting Skin Neoplasms: A Review of Berberine's Anticancer Properties](https://pubmed.ncbi.nlm.nih.gov/40710294/). *Cells*. PMID [40710294](https://pubmed.ncbi.nlm.nih.gov/40710294/) · [doi:10.3390/cells14141041](https://doi.org/10.3390/cells14141041) Berberine demonstrated anticancer properties against various skin neoplasms through modulation of apoptotic pathways, cell cycle arrest, and inhibition of tumor proliferation signaling. *2 further claims previously listed here could not be traced to a published paper and have been removed. An absence here means we could not identify the source, not that no work exists.* ## Recent safety updates - No serious hepatotoxicity linked to berberine despite wide-scale use; clinical trial biomarkers showed no toxic effects on liver, muscles, or kidneys. EFSA has called for additional data on long-term safety of berberine-containing food supplements - Topical application is well-tolerated; adverse reactions in clinical trials with Berberis aristata root extract were minor and comparable to placebo group. Oral berberine may interact with CYP3A4-metabolized drugs ## What is it made of? ### Key Active Markers - Berberine - Palmatine - Jatrorrhizine - Berbamine - Tannins - Oxyberberine - - Karachine - Taxilamine - **Analytical Methods:** HPLC fingerprinting, TLC (identity), LC-MS/MS (marker quantification) ## Dosage forms and preparation **Dosage Forms:** Churna (powder), Tablet, Capsule, Kashayam (decoction), Netra Bindu (eye drops), Taila (medicated oil), Kwath Ghana (solid extract) **Standard Dosage:** 3-6g powder twice daily; 500mg standardized extract capsule twice daily; 50-100ml decoction twice daily; eye drops as directed **Bioavailability:** Primary active berberine has notoriously low oral bioavailability (< 5%) due to extensive first-pass metabolism by CYP [enzymes](/glossary/compounds-d-g/#enzymes), P-glycoprotein efflux, and poor aqueous solubility. Enhancement strategies: co-administration with [Pippali](/herb/pippali/) ([piperine](/reference/piperine/) inhibits P-gp and CYP3A4, increasing berberine bioavailability 2-5 fold); solid lipid nanoparticle formulations increase AUC by 4-fold; berberine-phospholipid complex (phytosome) improves absorption; cyclodextrin inclusion complexes enhance solubility. Self-nanoemulsifying systems (SNEDDS) show 6-fold improvement in preclinical studies. **Optimal Timing:** Before meals with warm water for metabolic conditions; after meals for GI conditions to reduce mucosal irritation **Standardized Extract:** Standardized to NLT 5% berberine by HPLC (dried extract); concentrated extracts available at 85-97% berberine HCl. Extract ratio 10:1 to 20:1 typical for capsule formulations. **Shelf Life:** 2 years (powder); 3 years (tablet/capsule); 1 year (eye drops after opening); 2 years (eye drops unopened) **Storage:** Store in airtight, amber or opaque containers below 25 deg C, protected from light. Berberine degrades under UV exposure. Eye drops: store at 2-8 deg C, discard 28 days after opening. **Marker Compounds:** Berberine, Palmatine, Jatrorrhizine, Berbamine, Oxyberberine, [Columbamine](/glossary/compounds-c-d/#columbamine) ### Extraction Methods - Hydroalcoholic extraction (70:30 methanol:water) - Aqueous decoction (traditional) - Acid-water extraction (0.5% HCl) - Supercritical CO2 extraction for berberine enrichment - Ion-exchange chromatography for high-purity berberine isolation ### Synergistic Combinations - With [Pippali](/herb/pippali/) (Piper longum) - piperine enhances berberine bioavailability 5x - With [Haridra](/herb/haridra/) (Curcuma longa) for synergistic anti-inflammatory action - With Amalaki for diabetic management - With [Triphala](/herb/triphala/) for ophthalmic applications - With [Nimba](/herb/nimba/) for skin disorders and antimicrobial synergy --- Canonical version of this page: https://nighantu.ageayurveda.com/herb/daruharidra/ ## Sources - Amidha Ayurveda Herb Database (700+ herbs, CC-BY-4.0) - Web research (clinical trials, WHO monographs, safety databases) - Ayurvedic Pharmacopoeia of India Published by Age Ayurveda in the Nighantu. Educational reference only, not medical advice. Incorporates material from the Amidha Ayurveda Herb Database under CC BY 4.0.